<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="52009">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01965730</url>
  </required_header>
  <id_info>
    <org_study_id>816724</org_study_id>
    <nct_id>NCT01965730</nct_id>
  </id_info>
  <brief_title>Dosing of Amicar and Measure of Fibrinolysis by TEG During Cardiac Surgery</brief_title>
  <acronym>EACA</acronym>
  <official_title>The Effect of Standard vs Aggressive Dosing Regimens for Epsilon-aminocaproic Acid on a Quantifiable Parameter of Fibrinolysis as Measured by Thromboelastography</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Pennsylvania</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study hopes to determine the optimal antifibrinolytic dosing to decrease bleeding and
      blood transfusion after cardiac surgery without increasing adverse events
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Anticipated">September 2014</completion_date>
  <primary_completion_date type="Anticipated">September 2014</primary_completion_date>
  <phase>Phase 0</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator)</study_design>
  <primary_outcome>
    <measure>degree of fibrinolysis as measured by thromboelastography</measure>
    <time_frame>Length of cardiac surgery</time_frame>
    <safety_issue>No</safety_issue>
    <description>The primary objective of the study will be to determine if a change in EACA dosing for cardiac surgery cases involving circulatory arrest actually leads to a quantifiable change in the degree of fibrinolysis as measured by TEG.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Aortic Disease</condition>
  <arm_group>
    <arm_group_label>epsilon-aminocaproic acid (EACA)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>75mg/kg loading dose with infusion 15mg/kg/hr</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EACA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>125mg/kg loading dose of EACA followed by an infusion of EACA at 25mg/kg/hr for length of cardiac surgery.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>epsilon-aminocaproic acid (EACA)</intervention_name>
    <arm_group_label>epsilon-aminocaproic acid (EACA)</arm_group_label>
    <arm_group_label>EACA</arm_group_label>
    <other_name>Amicar</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ability to sign informed consent

          -  Elective cardiac surgery patients undergoing primary surgery involving circulatory
             arrest

        Exclusion Criteria:

          -  Inability to sign informed consent

          -  Baseline hypercoagulable condition as defined in medical record

          -  Coronary disease with untreated lesions or recent coronary stent placement

          -  Severe renal dysfunction (ESRD) as documented in medical record
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Prakash A Patel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pennsylvania</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mary S Hammond, BSN</last_name>
    <phone>2156623772</phone>
    <email>mary.hammond@uphs.upenn.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mary S Hammond, BSN</last_name>
      <email>mary.hammond@uphs.upenn.edu</email>
    </contact>
    <investigator>
      <last_name>Prakash A Patel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <lastchanged_date>October 17, 2013</lastchanged_date>
  <firstreceived_date>October 16, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>dilated ascending aorta</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Aortic Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>6-Aminocaproic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
